NCT04838327 Rare Subtypes of Gastrointestinal Cancers
| NCT ID | NCT04838327 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aarhus University Hospital |
| Condition | Cancer of Gastrointestinal Tract |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2021-08-16 |
| Primary Completion | 2025-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2021-08-16 with a primary completion date of 2025-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A single-arm prospective observational translational study of biomarkers in patients receiving targeted treatment for rare subtypes of cancer of the Gastrointestinal Tract.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of a rare subtype of GI cancer including BRAF V600E mutation, MSI-H, HER2 and others * Diagnosis of cancer of the gastrointestinal tract may be made by histo- or cyto-pathology, or by clinical and imaging criteria * Planned for targeted treatment * Age 18 years or older * Able to understand written information * Consent to samples for translational research Exclusion Criteria: * Conditions precluding translational blood sampling * Another concomitant cancer
Contact & Investigator
Louise B Callesen, MD
PRINCIPAL INVESTIGATOR
Experimental Clinical Oncology
Frequently Asked Questions
Who can join the NCT04838327 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer of Gastrointestinal Tract. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04838327 currently recruiting?
Yes, NCT04838327 is actively recruiting participants. Contact the research team at louicall@rm.dk for enrollment information.
Where is the NCT04838327 trial being conducted?
This trial is being conducted at Aarhus N, Denmark.
Who is sponsoring the NCT04838327 clinical trial?
NCT04838327 is sponsored by Aarhus University Hospital. The principal investigator is Louise B Callesen, MD at Experimental Clinical Oncology. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.